
    
      A randomized phase 2 study, involving patients with advanced non-small-cell lung cancer who
      had not previously received chemotherapy, compared paclitaxel and carboplatin Plus placebo
      with paclitaxel and carboplatin plus PEGylated endostatin, with PEGylated endostatin at a
      dose of 10 mg/m2 intravenously every weeks.
    
  